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Abstract
Background: Recent evidence from a large scale trial conducted in the United States indicates that enhancing
shared decision-making and improving knowledge, self-management, and provider communication skills to at-risk
patients can reduce health costs and utilisation of healthcare resources. Although this trial has provided a
significant advancement in the evidence base for disease management programs it is still left for such results to be
replicated and/or generalised for populations in other countries and other healthcare environments. This trial
responds to the limited analyses on the effectiveness of providing chronic disease management services through
telephone health coaching in Australia. The size of this trial and it’s assessment of cost utility with respect to
potentially preventable hospitalisations adds significantly to the body of knowledge to support policy and
investment decisions in Australia as well as to the international debate regarding the effect of disease
management programs on financial outcomes.
Methods: Intention to treat study applying a prospective randomised design comparing usual care with extensive
outreach to encourage use of telephone health coaching for those people identified from a risk scoring algorithm
as having a higher likelihood of future health costs. The trial population has been limited to people with one or
more of the following selected chronic conditions: namely, low back pain, diabetes, coronary artery disease, heart
failure, and chronic obstructive pulmonary disease. This trial will enrol at least 64,835 sourced from the
approximately 3 million Bupa Australia private health insured members located across Australia. The primary
outcome will be the total (non-maternity) cost per member as reported to the private health insurer (i.e. charged
to the insurer) 12 months following entry into the trial for each person. Study recruitment will be completed in
early 2012 and the results will be available in late 2013.
Discussion: If positive, CAPICHe will represent a potentially cost-effective strategy to improve health outcomes in
higher risk individuals with a chronic condition, in a private health insurance setting.
Trial Registration: Australian New Zealand Clinical Trials Registry reference: ACTRN12611000580976
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As growth in the prevalence of chronic disease increases
the economic burdens on the health system and on
society more broadly, approaches to ameliorating this
impact have received increasing attention. Advance in
medical science and management of both acute and
chronic conditions have led to greater proportions of
the population in many countries reaching older age.
The impact on healthcare delivery systems has been
compounded by lifestyle issues brought about by, for
example, changes in diet, food availability, and activity
levels. These changes have led to increasing financial
pressures on healthcare systems to cope with the
increased demand for health services [1-3].
Disease management - a term used to describe a wide
range of approaches designed to mitigate the progres-
sion and quality of life impacts of health conditions and
encourage adherence to recommended treatment plans
and self-care strategies [4] - has been promoted as a
way to improve quality of care, improve health out-
comes and lower costs, particularly for patients with
chronic disease [5-7].
Faced with double-digit healthcare inflation, disease
management has been widely used in the United States
by insurers, employers, and government with revenues
to provider organisations reported in 2007 to be
approaching $2 billion a year [8]. In addition, public
health care funders in the United States have also con-
sidered further investment in disease management as a
strategy to reduce health care expenditure [9]. However,
in a review conducted in 2007, the evidence for such
large scale investment into disease management pro-
grams to have a significant impact on financial out-
comes was labelled ‘inconclusive’. Beneficial claims of
disease management programs have been criticised on
the grounds that they have generally been anecdotal,
involve highly selected patients in closed systems of
care, or suffer from a number of biases, such as bias in
the recruitment or enrolment of participants [10].
To address the apparent lack of large-scale, methodo-
logically rigorous investigations into the effects of dis-
ease management on financial outcomes, a randomised
trial of telephone care-management within the United
States was conducted for a study population of 174,120
subjects [11]. The evidence from this large scale trial
indicated that enhancing shared decision-making and
improving knowledge, self-management, and provider
communication skills to at-risk patients can reduce
health costs and utilisation of healthcare resources.
Although this trial has provided a significant advance
in the evidence base for disease management programs
it remains to be seen whether such results can be repli-
cated and/or generalised for populations in other coun-
tries or other health environments. For example,
although the Australian health care system has a great
many similarities to that in the United States, there
remain significant differences in health financing, medi-
cal practice, and population risk differences. As such, it
is yet to be shown whether the telephonic health coach-
ing models that were effective in trials conducted within
the United States [11] will confer similar benefits within
the models of healthcare operating in Australia.
To date there have been few clinical trials of health
coaching or disease management programs in Australia
[1], and none of a similar scale or depth as that col-
lected within the United States. Moreover, trials that
have been conducted in Australia have generally only
taken a public health sector perspective, whereas health
care in Australia is provided both through public and
private health care providers and financed through both
private and public insurance schemes.
Although results arising from the public health sector
may be relevant to the private health sector, there
remain significant points of differentiation, such as case
mix, population demographics, financing, terms of
employment and waiting times [12-16].
The CAPICHe trial is a prospective study of at least
64,835 subjects, that will assess differences in costs and
hospital utilisation for a cohort actively offered a disease
management (health coaching) intervention compared
with a control group of persons who will be advised
that they can contact the coaching service and receive
advice if they so wish. This trial responds to the limited
large-scale analyses on the effectiveness of providing
chronic disease management services through telephone
health coaching in Australia. Furthermore, this trial pro-
vides data from the perspective of private health
insurers, an analysis that is often absent in the Austra-
lian literature. Moreover, the size of this trial and its
assessment of cost utility with respect to potentially pre-
ventable hospitalisations adds significantly to the body
of knowledge to support policy and investment decisions
in Australia as well as to the international debate
regarding the effect of disease management programs on
financial outcomes. This article outlines the design and
analysis plan for the CAPICHe trial.
Specific aims
T h eo b j e c t i v eo ft h es t u d yi st oe v a l u a t et h er e l a t i v e
impact on healthcare utilisation and cost of participants
in a disease management program provided through tel-
ephonic health coaching support versus usual care.
Trial Design and Methods
This is an intention to treat study applying a prospective
randomised design comparing usual care with extensive
outreach to encourage use of telephone health coaching.
The population has been targeted prior to randomisation
Byrnes et al. BMC Public Health 2012, 12:114
http://www.biomedcentral.com/1471-2458/12/114
Page 2 of 6as people identified on the basis of previous medical and
utilisation history using a risk scoring algorithm. The risk
targeting presumes to pre-select people believed to have
a high likelihood of further hospitalisation and health
costs in the short term, based on previous analysis of
population utilisation trends. The trial is limited to peo-
ple who have had a diagnosis of one or more selected
chronic conditions: namely, low back pain, diabetes, cor-
onary artery disease, heart failure, and chronic obstruc-
tive pulmonary disease. Figure 1 shows the design of the
study. Ethics approval was granted by Griffith University.
Participants
This trial will enrol at least 64,835 participants, sourced
from the approximately 3 million Bupa Australia health
fund members located across the country.
A series of inclusion and exclusion criteria have been
applied prior to randomisation to reduce the risk of
contamination of results from other disease manage-
ment programs available to the health funds’ members.
Health fund members who lose eligibility through cessa-
tion of health insurance (which is estimated at less than
4% per annum based on current experience with the
general insured population) will be counted only for
months they have health fund membership eligibility as
data will not be available thereafter.
Inclusion criteria include:
￿ 18-90 years of age;
￿ Hold hospital cover with Bupa Australia (and have
for at least 12-months continuously immediately prior);
￿ Have a valid Australian mailing address;
￿ Have claims evidence of diagnosis of low back pain,
diabetes, coronary artery disease, or chronic obstructive
pulmonary disease based on Bupa Health Dialog pro-
prietary identification systems that analyse participant
claims history to determine presence of disease;
￿ Are the highest risk member of their household
based on Bupa Health Dialog proprietary risk identifica-
tion systems that analyse predicted risk;
￿ Have claims-based predicted risk levels of greater
than 0.061, (which is equivalent to a predicted cost for
the following 12 months of $3,050 or more, in 2010
dollars).
Exclusion Criteria will include:
￿ Any individual who shares a household with a pre-
viously assigned study subject;
￿ Individuals targeted for and/or involved in poten-
tially similar services prior to study initiation;
￿ Individuals with claims evidence prior to study
initiation of:
○ End Stage Renal Disease
○ HIV/AIDS
○ Haemophilia
￿ Individuals with claims evidence of an organ trans-
plant prior to study initiation.
Randomisation and allocation concealment
Subjects are identified for enrolment each month based
on qualification of inclusion criteria including a mini-
mum risk score of 0.061. This is equivalent to a pre-
dicted cost for the following 12 months of $3,050 or
more (2010 Australian dollars). Risk scores are calcu-
lated monthly and each month, a sample of subjects
who meet the inclusion criteria are randomly selected
using the SurveySelect procedure in SAS [17]. The pro-
portion selected from those who meet the inclusion cri-
teria is dependent on the expected capacity of the
health coaches providing telephonic services. The sam-
ples are then randomised into the intervention or con-
trol groups. Randomisation is blinded and conducted
independently through the Griffith Clinical Trials Unit
Figure 1 Study design for CAPICHe.
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duce concordance between the intervention and control
groups on baseline demographics and risk score. Rando-
misation was created using SurveySelect procedure
using SAS [17] with the default simple random sampling
option and stratified by chronic condition with a 4:1
allocation ratio to intervention and control. For each
monthly batch of data, a seed value of nine digits was
obtained by the statistician using random number gen-
erator with replacement from 0 to 9 for each of the
nine digits. The SurveySelect procedure generates uni-
form random numbers using a prime modulus multipli-
cative generator with modulus 231 and multiplier
397204094. This means that it is very unlikely randomi-
sation will be repeated. The effectiveness of randomisa-
tion for each monthly batch of data was checked by
performing tests between the intervention and control
groups on total non-maternity cost, number of over-
night admitted, age, sex, and state of residential.
Blinding
This trial is considered tob eo p e ni nd e s i g nw h e r en o
method has been specifically used for blinding of partici-
pants, health coaches or data collection agents.
Interventions
Intervention Group
The Intervention Group will be eligible to receive dis-
ease management services from Bupa Health Dialog
including mailed program awareness notifications, out-
bound Health Coach outreach, and follow-up calls (a
minimum of one call in the first two months with no
maximum number of calls being set), access on an
inbound telephonic basis to Health Coaches, tailored
mailed educational material, tailored outreach material
designed to encourage individuals with specific risks to
talk with a Health Coach, and mailed Health Coach
selected educational and other material. Where English
is not their first language, clients can participate by hav-
ing assistance in the program from their nominated per-
sonal carer who can act as an interpreter.
Control Group
The control group will generally receive usual care but
are given the opportunity, via mail, to “opt-in” to receive
health coaching. Individuals randomly assigned to the
control group will receive a letter outlining the service
provided by Bupa Health Dialog. If a participant
assigned to the usual support control group actively
seeks health coach engagement, they will receive the
same service as that provided to a participant assigned
to the intervention group (i.e. health coaching). Health
coaches will have the same quality of information avail-
able about the members and will have all the same edu-
cational resources at their disposal as they do for the
intervention group.
All individuals assigned to the Control will be ana-
lysed as such regardless of whether they receive health
coaching or not. Experience in the USA [11] suggests
that the proportions of individuals in the control group
who actively seek health coaching with mailed outreach
only will be 3% or less. Therefore, the Control is consid-
ered to be an appropriate approximation of usual sup-
port and care. Moreover, the differentiation of service
levels between the intervention and control is therefore
expected to be quite high. To ensure this is the case in
the Australian setting, the number of members falling
into this category will be reviewed on a frequent and
regular basis.
Outcome measures
Primary outcome
The primary outcome will be the total (non-maternity)
cost per member as reported to the private health
insurer (i.e. charged to the insurer) one year post rando-
misation. The cost (i.e. the total benefit paid) is calcu-
lated as the sum of hospital, medical (excluding
Medicare Benefits Schedule component) and prostheses
claims. Ancillary benefits will not be included as the
role of the intervention in impacting on a range of bene-
fits including dental and optical is not sufficiently well
defined.
Secondary outcomes
Secondary outcome measures will include:
￿ Non-maternity costs in the intervention year per
member by type of service;
￿ Rates of inpatient (non-maternity) hospitalisations in
total in the intervention year;
￿ Rates of “impactable inpatient hospitalisations” in
the intervention year. “Impactable” inpatient hospitalisa-
tions are defined as those that are generally associated
with the pre-existing condition, essentially, excluding
those hospitalisations for which there could be little rea-
sonable expectation that telephone health coaching
could impact, for example, dialysis, chemotherapy for
cancer, transplants;
￿ Rates of inpatient (non-maternity) hospitalisations by
type of hospitalisation (medical, surgical, and other sub-
classifications) in the intervention year;
￿ Same day non- maternity admission rates in the
intervention year, and
￿ Rates of non-maternity inpatient bed days in the
intervention year.
Other measures
Ongoing monitoring of program activity in both the
intervention and control group will be regularly con-
ducted. Individuals who engage with a health coach will
be eligible to be randomly selected to participate in a
satisfaction survey about their health coaching
experiences.
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Each study subject will be followed continuously
through claims data collection until paid claims have
accrued for a full 12 month period after he or she is
randomised into intervention or control group. An addi-
tional four months will be allowed for the processing of
claims to ensure the majority of insurance claims data
have been collected within a reasonable period.
Sample size
Sample size calculations were performed based on the
coefficient of variation of the primary outcome measure
of predicted total non-maternity cost for each chronic
condition. A sampling ratio of 4:1 intervention group
participants for every one control group participant is
used to maximise the coverage for those to receive the
intervention. It is expected that not all those randomised
to the intervention group will be “reached” (directly
contacted by telephone), and of those reached, not all
will consent or engage in health coaching.
We have estimated the necessary sample size based on
two assumptions; 1. at least 30% of those randomised to
the intervention group will be engaged, and 2. those
engaged will have a 12.5% reduction in healthcare claims
over the 12-months of follow-up compared with the con-
trol group. This gives an overall expected effect size for
the intervention group of 3.75%. To detect a 3.75% reduc-
tion in total non-maternity costs at the 5% level of signifi-
cance with 80% power and the coefficient of variation of
2.43 (based on a sample of historical claims and observed
claims in a subsequent period), an overall sample size of
64,835 is required for an intent to treat analysis.
Data collection
Claims data collection
Bupa Australia claims data is accumulated as part of
standard business practice. As Bupa Australia’sa g e n t ,
Bupa Health Dialog has legal and open access to rele-
vant Bupa Australia claims data through a contractual
relationship with Bupa Australia. Claims data will be
extracted from Bupa Australia data systems.
Process measure data collection
Bupa Health Dialog health coaches will provide an array
of data on those interactions and may also collect facts
about the members to support their engagement with
the members. These data will be used to provide opti-
mal service to the participants and will be analysed to
support outcome assessments on their experiences. This
is independent of the trial and consistent with the health
professional role of the coaches.
Data analysis
This is an intention to treat study. The stratified rando-
mised sampling strategy is intended to minimise
baseline differences in key covariates that may influence
the outcomes. Statistical testing of costs per member
will be based on the natural logarithm due to the typi-
cally non-normal distribution of costs. The decision to
participate in health coaching could potentially indicate
differences in attitudes to prevention or compliance and
so have the potential to bias outcomes. Therefore, in
order to improve the precision of any test of differences
between the groups, ANCOVA may be used. Covariates
will include historical costs by service category, histori-
cal admission counts, age, gender, state of residence,
policy type, and targeted condition flags, in as much as
the resulting model is properly specified. Sub-group ana-
lysis of those with a recorded hospitalisation within 12
months prior to enrolment of the trial will be underta-
ken with respect to primary and secondary outcome
measures. We will report the trial in accordance with
the updated CONSORT statement [18].
Discussion
The CAPICHe trial responds to the limited analyses on
the effectiveness of providing chronic disease manage-
ment services through telephone health coaching. It will
provide an important step forward for Australian
research of the effectiveness of health coaching as well
as to the international debate regarding the effect of dis-
ease management programs on financial outcomes
through providing an important opportunity to assess
the generalisability of previous large scale trials within
the United States to other populations. The perspective
of private health insurers is often absent in the Austra-
lian literature, and this trial goes some way to addres-
sing this gap. If positive, CAPICHe will present evidence
that telephone health coaching service is a potentially
cost-effective strategy to improve health outcomes in
individuals with chronic disease in Australia.
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